Published in Heart Vessels on April 11, 2015
Efficient long-term survival of cell grafts after myocardial infarction with thick viable cardiac tissue entirely from pluripotent stem cells. Sci Rep (2015) 0.86
Intramyocardial delivery of VEGF165 via a novel biodegradable hydrogel induces angiogenesis and improves cardiac function after rat myocardial infarction. Heart Vessels (2015) 0.81
The efficacy of a multidisciplinary team approach in critical limb ischemia. Heart Vessels (2016) 0.77
Fibroblast growth factors as tissue repair and regeneration therapeutics. PeerJ (2016) 0.77
Intramyocardial delivery of bFGF with a biodegradable and thermosensitive hydrogel improves angiogenesis and cardio-protection in infarcted myocardium. Exp Ther Med (2017) 0.75
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg (2007) 14.17
Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet (2002) 7.11
Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg (1997) 5.88
Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature (1974) 4.58
Structural characterization and biological functions of fibroblast growth factor. Endocr Rev (1987) 3.40
Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet (2011) 2.88
Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 2.82
The clinical utility of a six-minute walk test in peripheral arterial occlusive disease patients. J Am Geriatr Soc (1998) 2.53
Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J (2012) 1.79
Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J (2008) 1.70
Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv (2011) 1.63
Protein release from gelatin matrices. Adv Drug Deliv Rev (1998) 1.61
Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis (2009) 1.57
Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. J Vasc Surg (2006) 1.49
Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg (2002) 1.21
Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension (2004) 1.19
Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther (2010) 1.16
Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. Biomaterials (1999) 1.15
Biodegradation of hydrogel carrier incorporating fibroblast growth factor. Tissue Eng (1999) 1.11
Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg (2011) 1.08
Neovascularization effect of biodegradable gelatin microspheres incorporating basic fibroblast growth factor. J Biomater Sci Polym Ed (1999) 1.02
Randomized and double-blind controlled clinical trial of extracorporeal cardiac shock wave therapy for coronary heart disease. Heart Vessels (2012) 0.98
Gene therapy in the treatment of peripheral arterial disease. Br J Surg (2011) 0.96
Management of peripheral vascular disease. Annu Rev Med (2005) 0.94
In vivo release and gene expression of plasmid DNA by hydrogels of gelatin with different cationization extents. J Control Release (2003) 0.93
Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation. J Vasc Surg (2005) 0.93
Tissue-specific consequences of the anti-adenoviral immune response: implications for cardiac transplants. Nat Med (1999) 0.90
Therapeutic angiogenesis by the controlled release of basic fibroblast growth factor for ischemic limb and heart injury: toward safety and minimal invasiveness. J Artif Organs (2004) 0.88
Long-term clinical outcome after intramuscular transplantation of granulocyte colony stimulating factor-mobilized CD34 positive cells in patients with critical limb ischemia. Atherosclerosis (2012) 0.88
Interventional management of critical limb ischemia in renal patients. Adv Chronic Kidney Dis (2008) 0.85
New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia. Circ J (2008) 0.83
Enhanced angiogenesis by gelatin hydrogels incorporating basic fibroblast growth factor in rabbit model of hind limb ischemia. Heart Vessels (2007) 0.82
Gelatin sheet incorporating basic fibroblast growth factor enhances sternal healing after harvesting bilateral internal thoracic arteries. J Thorac Cardiovasc Surg (2003) 0.81
A novel approach to reduce catheter-related infection using sustained-release basic fibroblast growth factor for tissue regeneration in mice. Heart Vessels (2007) 0.81
Effect of sarpogrelate treatment on the prognosis after endovascular therapy for critical limb ischemia. Heart Vessels (2013) 0.79
Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia. Circ J (2006) 0.79
The role of FGF-2 in renal fibrogenesis. Front Biosci (Schol Ed) (2009) 0.79
TcPO2 as an accurate predictor of therapy in limb salvage. Ann Vasc Surg (1996) 0.78
Advances in endovascular treatment of critical limb ischemia. Circ J (2011) 0.78
Current status of myocardial regeneration therapy. Gen Thorac Cardiovasc Surg (2012) 0.77
Sustained release of prostaglandin E1 potentiates the impaired therapeutic angiogenesis by basic fibroblast growth factor in diabetic murine hindlimb ischemia. Circ J (2008) 0.76
Inquiry into gene therapy widens. Nat Biotechnol (2000) 0.75
Transplantation of purified CD34+ cells in the treatment of critical limb ischemia. J Vasc Surg (2013) 0.75
Combined treatment with sustained-release basic fibroblast growth factor and heparin enhances neovascularization in hypercholesterolemic mouse hindlimb ischemia. Circ J (2007) 0.75
A muscle ultrasound score in the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol (2017) 1.39
Meibomian glands and ocular surface inflammation. Ocul Surf (2015) 0.90
Dual growth factor delivery from bilayered, biodegradable hydrogel composites for spatially-guided osteochondral tissue repair. Biomaterials (2014) 0.89
Efficient long-term survival of cell grafts after myocardial infarction with thick viable cardiac tissue entirely from pluripotent stem cells. Sci Rep (2015) 0.86
Generation of osteochondral tissue constructs with chondrogenically and osteogenically predifferentiated mesenchymal stem cells encapsulated in bilayered hydrogels. Acta Biomater (2013) 0.85
The regenerative effects of CCN2 independent modules on chondrocytes in vitro and osteoarthritis models in vivo. Bone (2013) 0.83
Interactions between BMP-7 and USAG-1 (uterine sensitization-associated gene-1) regulate supernumerary organ formations. PLoS One (2014) 0.81
Urinary neutrophil gelatinase-associated lipocalin: a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. PLoS One (2014) 0.80
A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head. Int Orthop (2015) 0.78
AMAP1 as a negative-feedback regulator of nuclear factor-κB under inflammatory conditions. Sci Rep (2014) 0.76
Coadministration of adipose-derived stem cells and control-released basic fibroblast growth factor facilitates angiogenesis in a murine ischemic hind limb model. J Vasc Surg (2015) 0.76
Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney. JCI Insight (2016) 0.75
Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells. PLoS One (2015) 0.75
Effects of Usag-1 and Bmp7 deficiencies on murine tooth morphogenesis. BMC Dev Biol (2016) 0.75
Evaluation of Gelatin Microparticles as Adherent-Substrates for Mesenchymal Stem Cells in a Hydrogel Composite. Ann Biomed Eng (2016) 0.75
Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats. PLoS One (2017) 0.75
Outcomes in surgically managed non-small-cell lung cancer patients with evidence of interstitial pneumonia identified on preoperative radiology or incidentally on postoperative histology. Interact Cardiovasc Thorac Surg (2015) 0.75
Efficacy of gelatin hydrogels incorporating triamcinolone acetonide for prevention of fibrosis in a mouse model. Regen Ther (2019) 0.75
Peptide modified mesenchymal stem cells as targeting delivery system transfected with miR-133b for the treatment of cerebral ischemia. Int J Pharm (2017) 0.75
Add-on effects of tadalafil in tamsulosin-treated patients with small benign prostatic enlargement: A randomized, placebo-controlled, double-blind, crossover study. Neurourol Urodyn (2019) 0.75
New risk factors for early- and late-onset cardiac rupture in ST-elevation myocardial infarction patients after primary percutaneous coronary intervention. J Cardiol (2021) 0.75
Sensitive and validated LC-MS/MS methods to evaluate mycophenolic acid pharmacokinetics and pharmacodynamics in hematopoietic stem cell transplant patients. Biomed Chromatogr (2015) 0.75